Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

June 30, 2029

Conditions
Cocaine Use Disorder
Interventions
DRUG

Sustained-release Dexamphetamine

"During the first week, patients will be individually titrated to the target dose of 90 mg/day, if tolerated. From the second week onwards, patients are prescribed 3 tablets (30 mg) per day, if tolerated. Titration can be slower but should be finished at the end of week 4. After 4 weeks dosages can no longer be increased, and only be reduced.~Patients will visit the treatment centre 2 times per week to take their study medication under supervision of the treatment staff and to receive take-home medication for the days in between study visits.~After 24 weeks patients will be randomized to either (double-blind) continuation or discontinuation (placebo) of SR-Dexamphetamine treatment to assess the consequences of discontinuation, during a 6 weeks period."

DRUG

Placebo

"Dispensed under the same conditions and with similar frequency as the investigational product (see above).~After 24 weeks study medication will be discontinued in the placebo group."

All Listed Sponsors
collaborator

Leiden University Medical Center

OTHER

collaborator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

collaborator

Radboud University Medical Center

OTHER

collaborator

The Netherlands Cancer Institute

OTHER

collaborator

Het Zwarte Gat

UNKNOWN

collaborator

Columbia University

OTHER

lead

Parnassia Addiction Research Centre

OTHER